Navigation Links
Scientists explore promising new option for first line of attack in lymphoma
Date:2/25/2014

A study led by Manchester scientists has shown promising results for a new treatment approach in follicular lymphoma.

Follicular lymphoma is a type of non-Hodgkin's lymphoma a blood cancer - that usually develops slowly. The majority of patients are diagnosed when their disease is at an advanced stage.

Recent improvements in treatment have included the use of antibodies to specifically target the tumour cells and to stimulate the patient's own immune system to attack their tumour. The use of such antibodies has improved treatment response, but unfortunately most patients still relapse.

Radioimmunotherapy where a radioactive substance is attached to the antibody has been shown to be successful in treating patients who had previously relapsed.

Now a team involving researchers from The University of Manchester part of the Manchester Cancer Research Centre - has investigated the use of radioimmunotherapy treatment in newly diagnosed patients.

The study published in the Journal of Clinical Oncology, looked at the effect of delivering the treatment in two fractions or doses this approach is thought to improve the penetration of the drug within larger tumours and also helps reduce the side effects associated with a full dose treatment.

Professor Tim Illidge, who led the research, said: "This was the first study to look at giving two fractions of radioimmunotherapy as an initial treatment in follicular lymphoma. We wanted to assess its safety and effectiveness in a group of high-risk patients who conventionally have done less well."

The researchers found that that their treatment plan was feasible and safe, with very few side effects.

"We saw a high overall response rate, of 94.4%, and 50 of the 72 (69.4%) patients treated in the study achieved complete response meaning their symptoms disappeared. These results are encouraging, but we need further studies in larger numbers of patients to fully compare this treatment to the standard treatment of 6-8 cycles of chemotherapy," added Professor Illidge.


'/>"/>
Contact: Alison Barbuti
alison.barbuti@manchester.ac.uk
44-016-127-58383
University of Manchester
Source:Eurekalert

Related medicine news :

1. Tel Aviv University scientists honored for proposals in melanoma research
2. Scientists call for screening mammography every 2 years for most women
3. NIH scientists find mechanism that helps HIV evade antibodies, stabilize key proteins
4. Scientists develop powerful new animal model for metastatic prostate cancer
5. NIH scientists map gene changes driving tumors in common pediatric soft-tissue cancer
6. Scripps Florida scientists find regulator of amyloid plaque buildup in Alzheimers disease
7. NCCS scientists discover gene regulation is dependent on protein ANP32E
8. Scientists make your stomach turn bright green if you have an ulcer
9. Scientists reduce protein crystal damage, improve pharmaceutical development
10. It's All In The Climate: New Study from Research Scientists at Florida International University Predict
11. Surviving ovarian cancer: Rutgers scientists attack drug resistant cancer cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... (PRWEB) , ... January 21, 2017 , ... Phytocéane ... Indian Ocean, isolated from the rest of the world with ZANZIBAR SHOWER GEL. Inspired ... Phytocéane used key ingredients, Virgin Coconut Oil and moisturizing vegetal coral to create this ...
(Date:1/21/2017)... ... January 21, 2017 , ... The ... Dr. Dan Holtzclaw in media for its creos™ line of bone regenerative products. ... Dr. Holtzclaw in which he utilizes creos™ allo.gain™ bone graft for a variety ...
(Date:1/20/2017)... ... January 20, 2017 , ... Doctor C LLC, a company ... January ECRM trade show to continue the marketing and distribution of its product, The ... for providing 400 percent better absorption than traditional vitamin C supplements. At the trade ...
(Date:1/20/2017)... ... January 20, 2017 , ... Michael and Betsy Brauser ... Cancer Institute. For Betsy, the clinical trial has been life-saving as she has ... worsened. , Betsy Brauser was diagnosed with ovarian cancer in 2009. She underwent ...
(Date:1/20/2017)... ... ... Word: Chocolate Biscuit”: a biographical account following a man who went on to support his ... Marlyn Ivey, born in Lynn Haven, Florida and at the age of 5, his family ... age, he joined the Navy and got married right out of boot camp. , ...
Breaking Medicine News(10 mins):
(Date:1/21/2017)... Mass. , Jan. 20, 2017 /PRNewswire/ ... Keystone Symposia Conference, "PI3K Pathways in Immunology, ... Inc. (NASDAQ: INFI ) ... immuno-oncology development candidate that selectively inhibits phosphoinositide-3-kinase-gamma ... able to help overcome resistance to checkpoint ...
(Date:1/20/2017)... , Jan. 20, 2017  Ethicon ... acquired Megadyne Medical Products, Inc., a privately ... and markets electrosurgical tools used in operating ... intelligence of Ethicon,s* advanced energy devices with ... a major step forward in Ethicon,s goal ...
(Date:1/20/2017)... 2017 Entscheidung fällt ... Die internationale humanitäre Stadt soll um knapp ... Seine Hoheit Scheich Muhammad bin ... Herrscher von Dubai , hat den ... (International Humanitarian City IHC) zu verdreifachen, um den Betrieb ...
Breaking Medicine Technology: